A/Prof Andrew Weickhardt is a medical oncologist and translational scientist at the Olivia Newton-John Cancer Centre in Melbourne. He has a research interest in genitourinary oncology, developmental therapeutics, and acquired resistance to targeted therapies (both immunotherapy and small molecule inhibitors) used in oncology. He was awarded $500k from Merck/MSD to conduct a first in world trial of pembrolizumab and chemoradiotherapy for patients with muscle invasive non metastatic bladder cancer (PCR-MIB). The trial is run through the Australia and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), with involvement of multiple Australian sites and lead bladder cancer urology, medical oncology and radiation oncology experts. His other current research involves both imaging and molecular biomarkers in genitourinary oncology, and is grant funded, involving international collaborators exploring prostate cancer imaging and bladder cancer targets.